“In the first half of 2024, we suspect many small biotech companies may end up being delisted or become shells into which other companies reverse merge.
But what will be the consequences of these difficulties for smaller companies in the biotech industry as a whole? “In the first half of 2024, we suspect many small biotech companies may end up being delisted or become shells into which other companies reverse merge. We also anticipate a flurry of M&A activity, especially with big pharma companies acquiring some larger biotechs, and there may also be a flurry of partnering activity between smaller biotechs and either larger biotechs or pharma companies,” said Tucker.